Aspirin plus clopidogrel vs aspirin alone for preventing cardiovascular events among patients at high risk for cardiovascular events
MP Donadini, M Bellesini, A Squizzato - JAMA, 2018 - jamanetwork.com
Clinical Question Among patients at high risk for or with established cardiovascular disease
(ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary …
(ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary …
Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High …
BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …
Antiplatelet therapy in populations at high risk of atherothrombosis.
Atherothrombosis is the most common cause of an acute ischemic event. Antiplatelet agents
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …
Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events
ADK Bowry, MA Brookhart, NK Choudhry - The American journal of …, 2008 - Elsevier
Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …
Although aspirin is the most widely used agent, randomized trials have assessed whether …
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …
studied in a broad population of patients at high risk for atherothrombotic events. Methods …
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
A Squizzato, M Bellesini, A Takeda… - Cochrane Database …, 2017 - cochranelibrary.com
Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional …
cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional …
[引用][C] Clinical trials update from the Annual Scientific Session of the American College of Cardiology 2006
The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management and Avoidance (CHARISMA) trial showed that the addition of clopidogrel to …
Management and Avoidance (CHARISMA) trial showed that the addition of clopidogrel to …
[引用][C] Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis.
KA Ballew - Evidence-based Medicine, 2006 - europepmc.org
Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials
TJ Helton, AA Bavry, DJ Kumbhani, S Duggal… - American journal of …, 2007 - Springer
Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …
Aspirin or clopidogrel for secondary prevention of cardiovascular events: is there a winner?
JM Gaspoz, P de Moerloose - The American journal of medicine, 2004 - amjmed.com
According to the World Health Organization, car-diovascular diseases caused 16.6 million
deaths worldwide (29.3% of all deaths) in 2001. Coronary heart disease was the leading …
deaths worldwide (29.3% of all deaths) in 2001. Coronary heart disease was the leading …